NEPAD: Better Endpoint for Progressive MS Trials?

(MedPage Today) -- Tweak to ' no evidence of disease activity ' standard stiffens criteria for progression
Source: MedPage Today Meeting Coverage - Category: Journals (General) Source Type: news
More News: General Medicine